Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

6.75USD
30 Sep 2016
Change (% chg)

$0.51 (+8.17%)
Prev Close
$6.24
Open
$6.28
Day's High
$6.83
Day's Low
$6.19
Volume
1,589,765
Avg. Vol
795,799
52-wk High
$7.27
52-wk Low
$2.38

ARRY.OQ

Chart for ARRY.OQ

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $1,094.11
Shares Outstanding(Mil.): 162.09
Dividend: --
Yield (%): --

Financials

  ARRY.OQ Industry Sector
P/E (TTM): -- 44.31 36.19
EPS (TTM): -0.65 -- --
ROI: -68.20 -0.23 13.87
ROE: -3,933.06 -2.85 14.78

BRIEF-Array Biopharma prices public offering at $6.25 per share

* Array Biopharma announces pricing of public offering of common stock

Sep 27 2016

BRIEF-Array Biopharma announces proposed public offering of common stock

* Array Biopharma announces proposed public offering of common stock

Sep 27 2016

CORRECTED-BRIEF-Array Biopharma, Pierre Fabre say Columbus phase 3 study met primary endpoint

* Array Biopharma and Pierre Fabre announce columbus phase 3 study of encorafenib plus binimetinib for BRAF-mutant melanoma met primary endpoint

Sep 26 2016

BRIEF-Array Biopharma announces Phase 3 Beacon CRC SPA agreement with FDA

* Array biopharma announces phase 3 beacon crc spa agreement with fda

Sep 14 2016

BRIEF-Array Biopharma enters into note purchase agreement

* On Sept 2, co entered into note purchase agreement - SEC filing

Sep 02 2016

BRIEF-Array Biopharma announces FDA acceptance of Binimetinib for patients with advanced NRAS-mutant melanoma

* Announces FDA acceptance Of Binimetinib NDA for patients with advanced NRAS mutant melanoma

Sep 01 2016

BRIEF-Array Biopharma presents data from cardiovascular trial

* Array presents data from cardiovascular trial with arry-797 at the european society of cardiology congress

Aug 30 2016

BRIEF-Array Biopharma files for mixed shelf of up to $300 mln

* Files for mixed shelf of up to $300 million - SEC filing Source text for Eikon: Further company coverage:

Aug 18 2016

BRIEF-Array Biopharma Q4 net loss $0.17 per share

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2016

Aug 04 2016

BRIEF-Array Biopharma names new CFO

* Array Biopharma announces appointment of Jason Haddock as chief financial officer

Jul 28 2016

Competitors

Earnings vs. Estimates